Acorda Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACORQ research report →
Companywww.acorda.com
Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
- CEO
- Ron Cohen
- IPO
- 2006
- Employees
- 102
- HQ
- Pearl River, NY, US
Price Chart
Valuation
- Market Cap
- $12.42K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.01
- EV/EBITDA
- -0.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.86%
- Op Margin
- -19.78%
- Net Margin
- -214.95%
- ROE
- 786.07%
- ROIC
- -25.57%
Growth & Income
- Revenue
- $117.63M · -0.79%
- Net Income
- $-252,854,000 · -283.60%
- EPS
- $-203.59 · -204.32%
- Op Income
- $-23,264,000
- FCF YoY
- 32.35%
Performance & Tape
- 52W High
- $18.00
- 52W Low
- $0.01
- 50D MA
- $0.15
- 200D MA
- $7.10
- Beta
- 1.69
- Avg Volume
- 22.12K
Get TickerSpark's AI analysis on ACORQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACORQ Coverage
We haven't published any research on ACORQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACORQ Report →